Tag: Sachs
Neurocrine Biosciences, Inc.: Goldman Sachs Still Positive
Marketzone with MT Newswires 2022 All the news about NEUROCRINE BIOSCIENCES, INC. Analyst Recommendations for NEUROCRINE BIOSCIENCES, INC. 2022…
Repare Therapeutics Inc.: Goldman Sachs to buy
Marketzone with MT Newswires 2022 All the news about REPARE THERAPEUTICS INC. REPARE THERAPEUTICS INC. Analyst Recommendations 2022 turnover…
Eli Lilly and Company: Goldman Sachs maintains its neutral opinion
Marketzone with MT Newswires 2022 All the news about ELI LILLY AND COMPANY Analyst recommendations on ELI LILLY AND COMPANY …
Madrigal Pharmaceuticals, Inc.: Positive opinion from Goldman Sachs
Marketzone with MT Newswires 2022 All the news about MADRIGAL PHARMACEUTICALS, INC. Analyst Recommendations for MADRIGAL PHARMACEUTICALS, INC. 2022…
Intellia Therapeutics, Inc.: Positive Opinion of Goldman Sachs
Marketzone with MT Newswires 2022 All the news about INTELLIA THERAPEUTICS, INC. Analyst Recommendations for INTELLIA THERAPEUTICS, INC. 2022…
Codiak BioSciences, Inc.: Positive Opinion of Goldman Sachs
Marketzone with MT Newswires 2022 All the news about CODIAK BIOSCIENCES, INC. Analyst Recommendations on CODIAK BIOSCIENCES, INC. 2022…
Relay Therapeutics, Inc.: Goldman Sachs remains long
Marketzone with MT Newswires 2022 All the news on RELAY THERAPEUTICS, INC. Analyst Recommendations on RELAY THERAPEUTICS, INC. 2022…
Kronos Bio, Inc.: Goldman Sachs favorable on the file
Marketzone with MT Newswires 2022 All the news about KRONOS BIO, INC. Analyst Recommendations for KRONOS BIO, INC. 2022…
Vertex Pharmaceuticals: Goldman Sachs optimistic on the file
Marketzone with MT Newswires 2022 All the news about VERTEX PHARMACEUTICALS Analyst recommendations on VERTEX PHARMACEUTICALS 2022 turnover 8,711M…
SpringWorks Therapeutics, Inc.: Goldman Sachs continues to buy
Marketzone with MT Newswires 2022 All the news about SPRINGWORKS THERAPEUTICS, INC. 08/05 SPRINGWORKS THERAPEUTICS, INC. : Goldman Sachs continues to buy…
1&1: Goldman Sachs neutral on the file
The recommendation of the broker Goldman Sachs is unchanged. Analyst Andrew Lee remains neutral on the issue. The target price is reduced…
HSBC HLDGS: Goldman Sachs maintains its buy recommendation
Analyst Gurpreet Singh Sahi of research firm Goldman Sachs considers the stock attractive and recommends it for purchase. The target price is…